In total, 610 patients were randomized to receive degarelix (administered via subcutaneous injection) at a starting dose of 240 mg, followed by maintenance doses of 80 mg/month (n = 207 ...

Firmagon has chemical characteristics and a novel mechanism of action, different to hormonal therapies. Administered as a deep subcutaneous injection, it rapidly reduces levels of testosterone by ...

Intention-to-treat analysis sets: degarelix 240/80 mg subcutaneous, n = 207; leuprolide 7.5 mg intramuscular, n= 201. *Injection-site reactions include injection-site pain, erythema, swelling ...